title: Cost-Effectiveness of Nicotine Patches for Smoking Cessation in Pregnancy: A Placebo Randomized Controlled Trial (SNAP).
abstract: BACKGROUND
  Smoking during pregnancy is the most important, preventable cause of adverse pregnancy outcomes including miscarriage, premature birth, and low birth weight with huge financial costs to the National Health Service. However, there are very few published economic evaluations of smoking cessation interventions in pregnancy and previous studies are predominantly U.S.-based and do not present incremental cost-effectiveness ratios (ICER). A number of studies have demonstrated cost-effectiveness of nicotine replacement therapy (NRT) in the general population, but this has yet to be tested among pregnant smokers.
  
  
  METHODS
  A cost-effectiveness analysis was undertaken alongside the smoking, nicotine, and pregnancy trial to compare NRT patches plus behavioral support to behavioral support alone, for pregnant women who smoked.
  
  
  RESULTS
  At delivery, biochemically verified quit rates were slightly higher at 9.4% in the NRT group compared to 7.6% in the control group (odds ratio = 1.26, 95% CI = 0.82-1.96), at an increased cost of around £90 per participant. Higher costs in the NRT group were mainly attributable to the cost of NRT patches (mean = £46.07). The incremental cost-effectiveness ratio associated with NRT was £4,926 per quitter and a sensitivity analysis including only singleton births yielded an ICER of £4,156 per quitter. However, wide confidence intervals indicated a high level of uncertainty.
  
  
  CONCLUSIONS
  Without a specific willingness to pay threshold, and due to high levels of statistical uncertainty, it is hard to determine the cost-effectiveness of NRT in this population. Furthermore, future research should address compliance issues, as these may dilute any potential effects of NRT, thus reducing the cost-effectiveness.
authors.affiliation: Mental health and Addiction Research Group, Department of Health Sciences, University of York, York, UK; holly.essex@york.ac.uk.
authors.forename: Holly N
authors.initials: HN
authors.lastname: Essex
authors.affiliation: Mental health and Addiction Research Group, Department of Health Sciences, University of York, York, UK;
authors.forename: Steve
authors.initials: S
authors.lastname: Parrott
authors.affiliation: Mental health and Addiction Research Group, Department of Health Sciences, University of York, York, UK;
authors.forename: Qi
authors.initials: Q
authors.lastname: Wu
authors.affiliation: Mental health and Addiction Research Group, Department of Health Sciences, University of York, York, UK;
authors.forename: Jinshuo
authors.initials: J
authors.lastname: Li
authors.affiliation: Division of Primary Care, NIHR School for Primary Care Research and UK Centre for Tobacco and Alcohol Studies, School of Medicine, University of Nottingham, Nottingham, UK.
authors.forename: Sue
authors.initials: S
authors.lastname: Cooper
authors.affiliation: Division of Primary Care, NIHR School for Primary Care Research and UK Centre for Tobacco and Alcohol Studies, School of Medicine, University of Nottingham, Nottingham, UK.
authors.forename: Tim
authors.initials: T
authors.lastname: Coleman
mesh_terms: D000328:Adult; D001521:Behavior Therapy; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D005260:Female; D006293:Health Promotion / Q000191:economics; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage* / Q000191:economics; D018722:Nicotinic Agonists / Q000008:administration & dosage* / Q000191:economics; D011247:Pregnancy; D011248:Pregnancy Complications / Q000191:economics / Q000517:prevention & control*; D011256:Pregnancy Outcome; D012907:Smoking / Q000628:therapy*; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods; D061485:Tobacco Use Cessation Devices / Q000191:economics*; D057968:Transdermal Patch; D016896:Treatment Outcome; D006113:United Kingdom; D055815:Young Adult
chemical_list: D018722:Nicotinic Agonists; D009538:Nicotine